JP2012533587A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533587A5 JP2012533587A5 JP2012520958A JP2012520958A JP2012533587A5 JP 2012533587 A5 JP2012533587 A5 JP 2012533587A5 JP 2012520958 A JP2012520958 A JP 2012520958A JP 2012520958 A JP2012520958 A JP 2012520958A JP 2012533587 A5 JP2012533587 A5 JP 2012533587A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- module
- cell
- compound
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 21
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 6
- 238000003776 cleavage reaction Methods 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000007017 scission Effects 0.000 claims 5
- 210000000172 cytosol Anatomy 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000004102 animal cell Anatomy 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 102000006240 membrane receptors Human genes 0.000 claims 3
- 229910052700 potassium Inorganic materials 0.000 claims 3
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- -1 IgM (μ) Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 claims 2
- 108700020471 RNA-Binding Proteins Proteins 0.000 claims 2
- 102000039471 Small Nuclear RNA Human genes 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004566 Transfer RNA Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims 2
- 230000004700 cellular uptake Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 101710083129 50S ribosomal protein L10, chloroplastic Proteins 0.000 claims 1
- 101710114762 50S ribosomal protein L11, chloroplastic Proteins 0.000 claims 1
- 101710082414 50S ribosomal protein L12, chloroplastic Proteins 0.000 claims 1
- 101710177347 50S ribosomal protein L15, chloroplastic Proteins 0.000 claims 1
- 108010066676 Abrin Proteins 0.000 claims 1
- 241000228212 Aspergillus Species 0.000 claims 1
- 102000003930 C-Type Lectins Human genes 0.000 claims 1
- 108090000342 C-Type Lectins Proteins 0.000 claims 1
- 102000007590 Calpain Human genes 0.000 claims 1
- 108010032088 Calpain Proteins 0.000 claims 1
- 108010049048 Cholera Toxin Proteins 0.000 claims 1
- 102000009016 Cholera Toxin Human genes 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 101710146739 Enterotoxin Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102100035233 Furin Human genes 0.000 claims 1
- 108090001126 Furin Proteins 0.000 claims 1
- 102000007563 Galectins Human genes 0.000 claims 1
- 108010046569 Galectins Proteins 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 claims 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 241000235648 Pichia Species 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 241000235070 Saccharomyces Species 0.000 claims 1
- 101150082971 Sgk1 gene Proteins 0.000 claims 1
- 108010079723 Shiga Toxin Proteins 0.000 claims 1
- 108010017898 Shiga Toxins Proteins 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 108010015865 Transferrins Proteins 0.000 claims 1
- 102000002070 Transferrins Human genes 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000002942 anti-growth Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000147 enterotoxin Substances 0.000 claims 1
- 231100000655 enterotoxin Toxicity 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 108091005601 modified peptides Proteins 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 150000004760 silicates Chemical class 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22766909P | 2009-07-22 | 2009-07-22 | |
| US61/227,669 | 2009-07-22 | ||
| PCT/EP2010/004512 WO2011009624A1 (en) | 2009-07-22 | 2010-07-22 | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012533587A JP2012533587A (ja) | 2012-12-27 |
| JP2012533587A5 true JP2012533587A5 (enExample) | 2013-09-12 |
Family
ID=42731966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520958A Pending JP2012533587A (ja) | 2009-07-22 | 2010-07-22 | 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120258104A1 (enExample) |
| EP (1) | EP2456470A1 (enExample) |
| JP (1) | JP2012533587A (enExample) |
| CA (1) | CA2768598A1 (enExample) |
| WO (1) | WO2011009624A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| EP2616045B1 (en) | 2010-09-15 | 2017-10-25 | Randall J. Mrsny | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| LT2646470T (lt) | 2010-11-30 | 2017-06-12 | F. Hoffmann-La Roche Ag | Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą |
| CA2825023A1 (en) * | 2011-01-26 | 2012-08-02 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| WO2012113413A1 (en) * | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| US9045750B2 (en) * | 2011-03-18 | 2015-06-02 | Yuelong Ma | Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3 |
| HK1200484A1 (zh) | 2011-09-14 | 2015-08-07 | Translate Bio Ma, Inc. | 多聚寡核苷酸化合物 |
| WO2013103146A1 (ja) * | 2012-01-07 | 2013-07-11 | 株式会社ボナック | アミノ酸骨格を有する一本鎖核酸分子 |
| US9475840B2 (en) | 2012-02-27 | 2016-10-25 | Universitat De Barcelona | Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs |
| CA2873779A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating mecp2 expression |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| US10174323B2 (en) | 2012-05-16 | 2019-01-08 | The General Hospital Corporation | Compositions and methods for modulating ATP2A2 expression |
| AU2013262700A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating hemoglobin gene family expression |
| US10058623B2 (en) | 2012-05-16 | 2018-08-28 | Translate Bio Ma, Inc. | Compositions and methods for modulating UTRN expression |
| EP2850186B1 (en) | 2012-05-16 | 2018-12-19 | Translate Bio MA, Inc. | Compositions and methods for modulating smn gene family expression |
| EP2857513A4 (en) | 2012-05-26 | 2016-05-25 | Bonac Corp | Single-stranded nucleic acid molecule controlling the expression of a gene transporter |
| WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| CA2902432A1 (en) | 2013-03-12 | 2014-10-09 | Molecular Templates, Inc. | Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types |
| DK3035969T3 (da) | 2013-08-19 | 2022-10-24 | S M Discovery Holdings Inc | Peptidsammensætning til nanofremføring målrettet to receptorer |
| CA2915728A1 (en) | 2013-08-21 | 2015-02-26 | Thomas Kramps | Respiratory syncytial virus (rsv) vaccine |
| EP3052632A4 (en) | 2013-10-04 | 2017-03-29 | Rana Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| JP6486836B2 (ja) | 2013-12-26 | 2019-03-20 | 学校法人東京医科大学 | 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途 |
| RU2697094C2 (ru) | 2013-12-27 | 2019-08-12 | Бонак Корпорейшн | ИСКУССТВЕННАЯ мкРНК С СООТВЕТСТВИЕМ ДЛЯ КОНТРОЛЯ ЭКСПРЕССИИ ГЕНОВ И ЕЕ ПРИМЕНЕНИЕ |
| US20160347798A1 (en) | 2014-01-27 | 2016-12-01 | Molecular Templates, Inc. | Mhc class i epitope delivering polypeptides and cell-targeted molecules for direct cell killing and immune stimulation via mhc class i presentation and methods regarding the same |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| EP3825327A1 (en) * | 2014-03-11 | 2021-05-26 | Molecular Templates, Inc. | Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs |
| US10273484B2 (en) | 2014-03-24 | 2019-04-30 | Riboxx Gmbh | Double-stranded RNA conjugates and their use |
| SI3139965T1 (sl) | 2014-05-07 | 2022-01-31 | Applied Molecular Transport Inc. | Fuzijske molekule, izpeljane iz toksina cholix, za peroralno dostavljanje biološko aktivnega tovora |
| JP6735237B2 (ja) | 2014-06-11 | 2020-08-05 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | プロテアーゼ切断耐性、志賀毒素ａサブユニットエフェクターポリペプチド及びそれを含む細胞標的化分子 |
| EP3200819A4 (en) * | 2014-09-30 | 2018-05-16 | The Medical College of Wisconsin, Inc. | Universal platform for targeting therapies to treat neurological diseases |
| WO2016073488A1 (en) * | 2014-11-04 | 2016-05-12 | The Regents Of The University Of California | Targeted delivery platform for delivery of therapeutics |
| AU2015368293B2 (en) | 2014-12-27 | 2021-07-22 | Bonac Corporation | Naturally occuring miRNA for controlling gene expression, and use of same |
| JP6444486B2 (ja) | 2015-02-05 | 2018-12-26 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | 志賀毒素ａサブユニットエフェクター領域を含む多価ｃｄ２０結合分子及びそれらの強化組成物 |
| HK1244031A1 (en) | 2015-03-27 | 2018-07-27 | Bonac Corporation | Single-chain nucleic acid molecule having delivery function and gene expression control ability |
| EP3303373B1 (en) | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| KR20180056750A (ko) * | 2015-10-05 | 2018-05-29 | 신젠타 파티서페이션즈 아게 | 리보핵산의 생물학적 활성을 보존하는 방법 |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| EP3608333A1 (en) | 2016-12-07 | 2020-02-12 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
| CN110536695B (zh) | 2017-01-25 | 2024-05-10 | 分子模板公司 | 包括去免疫化的志贺毒素a亚基效应子和cd8+ t细胞表位的细胞靶向分子 |
| CN118638788A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| EP4316586A3 (en) | 2018-03-08 | 2024-05-08 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| EP3768708A4 (en) * | 2018-03-23 | 2022-08-03 | The Regents of the University of California | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY |
| WO2019204272A1 (en) | 2018-04-17 | 2019-10-24 | Molecular Templates, Inc. | Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds |
| US20210139892A1 (en) * | 2018-07-05 | 2021-05-13 | The Regents Of The University Of California | Compositions and methods for delivery of rna to a cell |
| IL282986B2 (en) | 2018-11-07 | 2024-01-01 | Applied Molecular Transport Inc | Colics-derivative carriers for oral administration of heterologous cargo |
| PL3650037T3 (pl) | 2018-11-07 | 2022-06-06 | Applied Molecular Transport Inc. | Konstrukty dostarczające do transcytozy i powiązane z nimi sposoby |
| CA3150859A1 (en) | 2019-08-16 | 2021-02-25 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
| EP3868882A1 (en) * | 2020-02-21 | 2021-08-25 | European Molecular Biology Laboratory | Archaeal pyrrolysyl trna synthetases for orthogonal use |
| MX2022011499A (es) | 2020-03-19 | 2022-10-07 | Avidity Biosciences Inc | Composiciones y metodos para tratar la distrofia muscular facioescapulohumeral. |
| US20230158061A1 (en) * | 2020-04-23 | 2023-05-25 | Cornell University | Nanotherapy Targeting RHAMM-Positive Tumors |
| CA3231330A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| EP4422679A4 (en) * | 2021-10-26 | 2025-11-12 | Navicure Biopharmaceuticals Ltd | Immunogenic fusion proteins against coronavirus |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4957773A (en) | 1989-02-13 | 1990-09-18 | Syracuse University | Deposition of boron-containing films from decaborane |
| DE69629580D1 (de) * | 1995-10-13 | 2003-09-25 | Us Gov Health & Human Serv | Immunotoxin enthaltend ein disulfid-stabilisiertes antikörperfragment |
| WO1998020135A2 (en) * | 1996-11-06 | 1998-05-14 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Protease-activatable pseudomonas exotoxin a-like proproteins |
| US6740643B2 (en) | 1999-01-21 | 2004-05-25 | Mirus Corporation | Compositions and methods for drug delivery using amphiphile binding molecules |
| US8211468B2 (en) | 1999-06-07 | 2012-07-03 | Arrowhead Madison Inc. | Endosomolytic polymers |
| US6743893B2 (en) | 2000-11-30 | 2004-06-01 | The Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| US7314625B2 (en) * | 2000-12-21 | 2008-01-01 | The United States As Represented By The Secretary Of The Department Of Health And Human Services | Chimeric protein comprising non-toxic Pseudomonas exotoxin A and Type IV pilin sequences |
| AU2002360353A1 (en) | 2001-12-11 | 2003-06-23 | University Of Iowa Research Foundation | Receptor-targeted adenoviral vectors |
| JP4597976B2 (ja) | 2003-04-17 | 2010-12-15 | アルナイラム ファーマシューティカルズ インコーポレイテッド | 修飾ｉＲＮＡ剤 |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| CA2529752A1 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
| US20100240597A1 (en) * | 2007-06-15 | 2010-09-23 | Arkansas State University | Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same |
| EP2205740A2 (en) | 2007-10-02 | 2010-07-14 | Rxi Pharmaceuticals Corp. | Tripartite rnai constructs |
-
2010
- 2010-07-22 WO PCT/EP2010/004512 patent/WO2011009624A1/en not_active Ceased
- 2010-07-22 US US13/386,347 patent/US20120258104A1/en not_active Abandoned
- 2010-07-22 CA CA2768598A patent/CA2768598A1/en not_active Abandoned
- 2010-07-22 JP JP2012520958A patent/JP2012533587A/ja active Pending
- 2010-07-22 EP EP10737781A patent/EP2456470A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012533587A5 (enExample) | ||
| US8691580B2 (en) | Single chemical entities and methods for delivery of oligonucleotides | |
| US20170137815A1 (en) | Novel single chemical entities and methods for delivery of oligonucleotides | |
| US10221205B2 (en) | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | |
| Yuan et al. | A novel poly (L-glutamic acid) dendrimer based drug delivery system with both pH-sensitive and targeting functions | |
| Varner et al. | Recent advances in engineering polyvalent biological interactions | |
| JP2012529891A5 (enExample) | ||
| AU2019230230B2 (en) | Toxin-derived delivery constructs for oral delivery | |
| Kristensen et al. | Routes for drug translocation across the blood-brain barrier: exploiting peptides as delivery vectors | |
| He et al. | Combinatorial optimization of sequence-defined oligo (ethanamino) amides for folate receptor-targeted pDNA and siRNA delivery | |
| De Martini et al. | Cell-penetrating peptides as valuable tools for nose-to-brain delivery of biological drugs | |
| CA2623659A1 (en) | Targeted delivery of compounds using multimerization technology | |
| EP3315139B1 (en) | A delivery system for targeted delivery of a therapeutically active payload | |
| KR101647804B1 (ko) | 신규 세포투과 펩타이드 및 이의 용도 | |
| JP2022544882A (ja) | ペイロード送達のための組成物および粒子 | |
| MX2013002939A (es) | Sistemas y metodos de suministro de agentes bioactivos mediante el uso de secuencias transportadoras derivadas de toxinas. | |
| Liu et al. | Toward artificial immunotoxins: traceless reversible conjugation of RNase A with receptor targeting and endosomal escape domains | |
| Pae et al. | Peptide-mediated delivery: an overview of pathways for efficient internalization | |
| US20140206596A1 (en) | Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions | |
| CN111093718A (zh) | 治疗性纳米缀合物及其用途 | |
| Li et al. | Targeted delivery of drugs for liver fibrosis | |
| US7314956B2 (en) | Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell | |
| CN112105376A (zh) | 用于经口递送的毒素衍生的递送构建体 | |
| Gabathuler | Development of new peptide vectors for the transport of therapeutic across the blood–brain barrier | |
| Futami et al. | Exploiting protein cationization techniques in future drug development |